儿科患者的区域柠檬酸抗凝:处理实践要点。

IF 1.8 3区 医学 Q3 HEMATOLOGY
Zaccaria Ricci, Akash Deep, Stuart L Goldstein
{"title":"儿科患者的区域柠檬酸抗凝:处理实践要点。","authors":"Zaccaria Ricci, Akash Deep, Stuart L Goldstein","doi":"10.1159/000548786","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Regional citrate anticoagulation (RCA) for continuous renal replacement therapy (CRRT) has been shown to be safe and effective both in adult and children. The equipment and the solutions available in the pediatric setting are the same as in adults.</p><p><strong>Summary: </strong>Currently three commercially available citrate formulations for RCA during continuous renal replacement therapy CRRT are present: concentrated (4% trisodium citrate, 136 mmol/L), semi-concentrated (anticoagulant dextrose-A, ACD-A, 75 mmol/L) and diluted (Prismocitrate/Regiocit, 18 mmol/L). RCA is delivered as a predilution infusion solution, therefore its volume in dedicated commercially available citrate solutions impacts continuous renal replacement (CRRT) dose, filtration fraction, circuit pressures and fluids flow. These aspects represent crucial details in the pediatric setting, and its relevance is more important as smaller is the patient body weight. Thus, when RCA is prescribed in children, the blood pump flow rate, the dose, the load and the concentration of citrate, and the patient's ability to metabolize citrate should be considered carefully and specifically contextualized on the citrate concentration available in each center.</p><p><strong>Conclusion: </strong>This technical review will describe these practice concepts that should be known in detail by the clinician approaching RCA in the pediatric setting.</p><p><strong>Key messages: </strong>Citrate \"dose\" is the citrate concentration in the blood running in the CRRT circuit. Citrate \"load\" represents the mass of citrate that is delivered to the circuit per each treatment hour. For a given citrate dose and blood flow rate, very different CRRT settings, sodium loads, filtration fractions, and dialytic doses are delivered by choosing the different formulations.</p>","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"1-7"},"PeriodicalIF":1.8000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Regional Citrate Anticoagulation in Pediatric Patients: Dealing With Practice Points.\",\"authors\":\"Zaccaria Ricci, Akash Deep, Stuart L Goldstein\",\"doi\":\"10.1159/000548786\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Regional citrate anticoagulation (RCA) for continuous renal replacement therapy (CRRT) has been shown to be safe and effective both in adult and children. The equipment and the solutions available in the pediatric setting are the same as in adults.</p><p><strong>Summary: </strong>Currently three commercially available citrate formulations for RCA during continuous renal replacement therapy CRRT are present: concentrated (4% trisodium citrate, 136 mmol/L), semi-concentrated (anticoagulant dextrose-A, ACD-A, 75 mmol/L) and diluted (Prismocitrate/Regiocit, 18 mmol/L). RCA is delivered as a predilution infusion solution, therefore its volume in dedicated commercially available citrate solutions impacts continuous renal replacement (CRRT) dose, filtration fraction, circuit pressures and fluids flow. These aspects represent crucial details in the pediatric setting, and its relevance is more important as smaller is the patient body weight. Thus, when RCA is prescribed in children, the blood pump flow rate, the dose, the load and the concentration of citrate, and the patient's ability to metabolize citrate should be considered carefully and specifically contextualized on the citrate concentration available in each center.</p><p><strong>Conclusion: </strong>This technical review will describe these practice concepts that should be known in detail by the clinician approaching RCA in the pediatric setting.</p><p><strong>Key messages: </strong>Citrate \\\"dose\\\" is the citrate concentration in the blood running in the CRRT circuit. Citrate \\\"load\\\" represents the mass of citrate that is delivered to the circuit per each treatment hour. For a given citrate dose and blood flow rate, very different CRRT settings, sodium loads, filtration fractions, and dialytic doses are delivered by choosing the different formulations.</p>\",\"PeriodicalId\":8953,\"journal\":{\"name\":\"Blood Purification\",\"volume\":\" \",\"pages\":\"1-7\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Purification\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000548786\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Purification","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000548786","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:区域柠檬酸抗凝(RCA)用于持续肾替代治疗(CRRT)已被证明在成人和儿童中都是安全有效的。儿童环境中可用的设备和解决方案与成人相同。总结:目前市售的用于RCA持续肾替代治疗CRRT期间的柠檬酸盐制剂有三种:浓缩(4%柠檬酸三钠,136 mmol/L)、半浓缩(抗凝葡萄糖- a, ACD-A, 75 mmol/L)和稀释(Prismocitrate/Regiocit, 18 mmol/L)。RCA作为预稀释输注溶液,因此其在专用市售柠檬酸盐溶液中的体积会影响持续肾替代(CRRT)剂量、过滤分数、回路压力和流体流量。这些方面代表了儿科环境中的关键细节,并且随着患者体重越小,其相关性就越重要。因此,在给儿童开RCA处方时,应仔细考虑血泵流速、剂量、柠檬酸盐负荷和浓度,以及患者代谢柠檬酸盐的能力,并具体考虑各中心可用的柠檬酸盐浓度。结论:这篇技术综述将描述这些实践概念,这些概念是临床医生在儿科环境中进行RCA时应该详细了解的。关键信息:柠檬酸盐“剂量”是在CRRT回路中运行的血液中的柠檬酸盐浓度。柠檬酸盐“负荷”表示每处理小时输送到回路的柠檬酸盐的质量。对于给定的柠檬酸剂量和血流量,通过选择不同的配方,可以提供非常不同的CRRT设置、钠负荷、过滤分数和透析剂量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Regional Citrate Anticoagulation in Pediatric Patients: Dealing With Practice Points.

Background: Regional citrate anticoagulation (RCA) for continuous renal replacement therapy (CRRT) has been shown to be safe and effective both in adult and children. The equipment and the solutions available in the pediatric setting are the same as in adults.

Summary: Currently three commercially available citrate formulations for RCA during continuous renal replacement therapy CRRT are present: concentrated (4% trisodium citrate, 136 mmol/L), semi-concentrated (anticoagulant dextrose-A, ACD-A, 75 mmol/L) and diluted (Prismocitrate/Regiocit, 18 mmol/L). RCA is delivered as a predilution infusion solution, therefore its volume in dedicated commercially available citrate solutions impacts continuous renal replacement (CRRT) dose, filtration fraction, circuit pressures and fluids flow. These aspects represent crucial details in the pediatric setting, and its relevance is more important as smaller is the patient body weight. Thus, when RCA is prescribed in children, the blood pump flow rate, the dose, the load and the concentration of citrate, and the patient's ability to metabolize citrate should be considered carefully and specifically contextualized on the citrate concentration available in each center.

Conclusion: This technical review will describe these practice concepts that should be known in detail by the clinician approaching RCA in the pediatric setting.

Key messages: Citrate "dose" is the citrate concentration in the blood running in the CRRT circuit. Citrate "load" represents the mass of citrate that is delivered to the circuit per each treatment hour. For a given citrate dose and blood flow rate, very different CRRT settings, sodium loads, filtration fractions, and dialytic doses are delivered by choosing the different formulations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Blood Purification
Blood Purification 医学-泌尿学与肾脏学
CiteScore
5.80
自引率
3.30%
发文量
69
审稿时长
6-12 weeks
期刊介绍: Practical information on hemodialysis, hemofiltration, peritoneal dialysis and apheresis is featured in this journal. Recognizing the critical importance of equipment and procedures, particular emphasis has been placed on reports, drawn from a wide range of fields, describing technical advances and improvements in methodology. Papers reflect the search for cost-effective solutions which increase not only patient survival but also patient comfort and disease improvement through prevention or correction of undesirable effects. Advances in vascular access and blood anticoagulation, problems associated with exposure of blood to foreign surfaces and acute-care nephrology, including continuous therapies, also receive attention. Nephrologists, internists, intensivists and hospital staff involved in dialysis, apheresis and immunoadsorption for acute and chronic solid organ failure will find this journal useful and informative. ''Blood Purification'' also serves as a platform for multidisciplinary experiences involving nephrologists, cardiologists and critical care physicians in order to expand the level of interaction between different disciplines and specialities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信